NCT06855316

Brief Summary

This randomized controlled trial explores the impact of a combined transcranial and peripheral electromagnetic stimulation over the potential correlation between psychological well-being and recovery outcomes of young athletes experiencing Delayed Onset Muscle Soreness.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 5, 2025

Completed
19 days until next milestone

Study Start

First participant enrolled

February 24, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 3, 2025

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 3, 2025

Completed
4 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 7, 2025

Completed
Last Updated

March 3, 2025

Status Verified

February 1, 2025

Enrollment Period

7 days

First QC Date

February 5, 2025

Last Update Submit

February 26, 2025

Conditions

Keywords

transcraneal magnetic stimulationdelay onset muscle sorenesspsychological profile

Outcome Measures

Primary Outcomes (5)

  • Big Five Personality Trait Short Questionnaire (Spanish version)

    This tool is used to evaluate five core personality dimensions: neuroticism, extraversion, openness, agreeableness, and conscientiousness (Airagnes et al., 2021). The abbreviated version contains 10 items rated on a 5-point Likert scale, where 1 indicates "completely disagree" and 5 represents "completely agree." An example item from this questionnaire is, "I see myself as a person who gets nervous easily." This measure provided insight into the stable personality characteristics of the athletes and their potential impact on recovery and pain perception.Each item is rated on a Likert scale, typically ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). Scores for each trait are summed up separately, with higher scores indicating stronger presence of that personality trait.

    Participants will complete questionnaires at 2 time points: just before treatment and after de last treatment (3 days after the first time frame).

  • State-Trait Anxiety Inventory (STAI, Spanish version)

    To assess anxiety levels, the STAI will be used. Participants rated their responses on a 4-point Likert scale, where 1 means "not at all" and 4 means "very much," reflecting their state and trait anxiety. This measure allowed for an analysis of how anxiety levels might correlate with recovery outcomes and subjective pain experiences. It consists of 40 items, divided into two subscales: STAI-S (State Anxiety, 20 items): Assesses temporary feelings of anxiety in a specific moment. STAI-T (Trait Anxiety, 20 items): Measures a person's general tendency to experience anxiety over time. Each item is rated on a 4-point Likert scale: STAI-S: 1 (Not at all) to 4 (Very much so) STAI-T: 1 (Almost never) to 4 (Almost always) Scores range from 20 to 80 for each subscale, with higher scores indicating greater anxiety levels. The STAI is widely used in both clinical and research settings to assess anxiety in different populations.

    Participants will complete questionnaires at 2 time points: just before treatment and after de last treatment (3 days after the first time frame)

  • Acceptance and Action Questionnaire-II (AAQ-II, Spanish version)

    The AAQ-II measures psychological inflexibility and experiential avoidance, which are critical in understanding how individuals cope with discomfort and stress (Carreira-Míguez et al., 2022). The 7-item questionnaire uses a 7-point Likert scale (0 = "never true" to 7 = "always true"), with higher scores indicating greater levels of psychological distress.The total score ranges from 7 to 49, with higher scores indicating greater experiential avoidance and psychological inflexibility, while lower scores reflect higher psychological flexibility. This scale is commonly used in clinical and research settings to evaluate mental health and intervention outcomes.

    Participants will complete questionnaires at 2 time points: just before treatment and after de last treatment (3 days after the first time frame)

  • UCLA Loneliness Scale (Spanish version):

    The Spanish version of the Three-Item Loneliness Scale will be administered to assess perceived social isolation. Participants rated each of the three items on a 3-point scale, with 1 meaning "never" and 3 meaning "frequently." This scale helped to explore the role of social support and perceived isolation in recovery from physical exertion.The scale consists of 20 items, each rated on a 4-point Likert scale: 1. (Never) 2. (Rarely) 3. (Sometimes) 4. (Often) The total score ranges from 20 to 80, with higher scores indicating greater levels of loneliness. There is no strict cutoff, but higher scores generally reflect more significant perceived loneliness.

    Participants will complete questionnaires at 2 time points: just before treatment and after de last treatment (3 days after the first time frame)

  • Zung Self-Rating Depression Scale (Spanish version):

    This self-applied scale contains 20 items designed to assess the severity of depressive symptoms, with both positive and negative formulations. The Zung scale's high specificity (over 80%) makes it a reliable tool for evaluating depression levels in the study's population (Carreira-Míguez et al., 2022). These baseline psychological assessments enabled the researchers to correlate psychological variables with recovery markers throughout the study.t consists of 20 questions, each evaluating various aspects of depression, including mood, physical symptoms, and psychomotor activity. Scoring Each question is rated on a 4-point Likert scale: 1. (A little of the time) 2. (Some of the time) 3. (Good part of the time) 4. (Most of the time) The total score ranges from 20 to 80, with higher scores indicating more severe depression: 20-44: Normal range 45-59: Mild depression 60-69: Moderate to marked depression 70-80: Severe depression

    Participants will complete questionnaires at 2 time points: just before treatment and after de last treatment (3 days after the first time frame)

Study Arms (4)

control/placebo group

PLACEBO COMPARATOR

Participants will be treated using the same device used in active stimulation groups, but the device will be turned off, thus providing a placebo effect. To maintain the placebo integrity, a pre-recorded sound mimicking the active device will be played during the session. Additionally, participants in the transcranial component will wear the machine's flap, similar to the TMS application, to further simulate the experience of active treatment. This method will ensure that the placebo control will be robust, allowing for accurate comparison with active treatments.

Device: electromagnetic stimulation

Super Inductive (P) Group

EXPERIMENTAL

Participants in the Super Inductive (P) group will receivePeripheral Electromagnetic Stimulation (PES) following a Long-Term Potentiation (LTP) protocol. This protocol involved five cycles of stimulation at a frequency of 100 Hz, each lasting for 5 seconds, with a rest interval of 55 seconds between cycles. The total duration of the PES treatment will be approximately 10 minutes, as suggested by Lang et al. (2007) and Milanović et al. (2011) (Lang et al., 2007; Milanović et al., 2011). This stimulation aimes to enhance peripheral nerve activation and support recovery through localized neuromodulation.

Device: electromagnetic stimulation

Transcranial (T) Group

EXPERIMENTAL

Participants in the Transcranial (T) group will get Transcranial Magnetic Stimulation (TMS) targeting at the primary motor cortex (M1). The protocol will be based on the findings of Dietmann et al. (2023) and Todd et al. (2003), consisting of the delivery of 2000 pulses of TMS over a minimum duration of 20 minutes (Dietmann et al., 2023; Todd et al., 2003). This intervention aimes to modulate cortical excitability, potentially enhancing muscle recovery through central nervous system adaptation.

Device: electromagnetic stimulation

Combined Stimulation (Comb) Group

EXPERIMENTAL

Participants in the Combined (Comb) group will receive both TMS and PES simultaneously, providing a synergistic intervention aimed at optimizing recovery outcomes. The combined stimulation session will last 30 minutes, integrating the benefits of both central and peripheral modulation. This dual approach targets the M1 region for central effects while also stimulating peripheral nerves to promote localized recovery processes.

Device: electromagnetic stimulation

Interventions

After performing a high-intensity eccentric exercise session, participants will undergo a daily session of transcranial and/or peripheral magnetic stimulation for three days. The objective is to enhance nerve conduction, which, according to the latest theories on DOMS, may be the cause of decreased athletic performance

Combined Stimulation (Comb) GroupSuper Inductive (P) GroupTranscranial (T) Groupcontrol/placebo group

Eligibility Criteria

Age18 Years - 35 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • be male,
  • aged between 18 and 35 years
  • engage in regular exercise at least three times per week for a minimum of one year
  • have no hypersensitivity to the areas designated for peripheral stimulation
  • be free from chronic conditions incompatible with exercise performance
  • have no recent musculoskeletal injuries to the lower limbs within the past six months,
  • be non-smokers
  • possess the cognitive capacity to understand the study's objectives and procedures.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alberto Sanchez Sierra

Toledo, TOLEDO, 45007, Spain

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
the outcome assessor will not know in which group is each participant, and the investigator will receive the data without knowing which data is from which group. Transcraneal magnetic stimulation in the placebo group was "applied"only with the sound reproduced by a speaker,remembering that the application of TMS is subthreshold, so the patient does not know if we are appying it or not, but all of them will here the same sound of the device.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Sierra Varona SL and professor at UCLM

Study Record Dates

First Submitted

February 5, 2025

First Posted

March 3, 2025

Study Start

February 24, 2025

Primary Completion

March 3, 2025

Study Completion

March 7, 2025

Last Updated

March 3, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

all IPD that underlie results in a publication

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
after publication during one year.

Locations